FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer
-
Published:2024-06-26
Issue:7
Volume:16
Page:1533-1559
-
ISSN:1757-4684
-
Container-title:EMBO Molecular Medicine
-
language:en
-
Short-container-title:EMBO Mol Med
Author:
Lorito NiclaORCID, Subbiani AngelaORCID, Smiriglia Alfredo, Bacci MarinaORCID, Bonechi Francesca, Tronci Laura, Romano ElisabettaORCID, Corrado Alessia, Longo Dario LivioORCID, Iozzo MartaORCID, Ippolito LuigiORCID, Comito Giuseppina, Giannoni ElisaORCID, Meattini Icro, Avgustinova Alexandra, Chiarugi PaolaORCID, Bachi AngelaORCID, Morandi AndreaORCID
Abstract
AbstractTriple-negative breast cancer (TNBC) has limited therapeutic options, is highly metastatic and characterized by early recurrence. Lipid metabolism is generally deregulated in TNBC and might reveal vulnerabilities to be targeted or used as biomarkers with clinical value. Ferroptosis is a type of cell death caused by iron-dependent lipid peroxidation which is facilitated by the presence of polyunsaturated fatty acids (PUFA). Here we identify fatty acid desaturases 1 and 2 (FADS1/2), which are responsible for PUFA biosynthesis, to be highly expressed in a subset of TNBC with a poorer prognosis. Lipidomic analysis, coupled with functional metabolic assays, showed that FADS1/2 high-expressing TNBC are susceptible to ferroptosis-inducing agents and that targeting FADS1/2 by both genetic interference and pharmacological approach renders those tumors ferroptosis-resistant while unbalancing PUFA/MUFA ratio by the supplementation of exogenous PUFA sensitizes resistant tumors to ferroptosis induction. Last, inhibiting lipid droplet (LD) formation and turnover suppresses the buffering capacity of LD and potentiates iron-dependent cell death. These findings have been validated in vitro and in vivo in mouse- and human-derived clinically relevant models and in a retrospective cohort of TNBC patients.
Funder
Fondazione AIRC per la ricerca sul cancro ETS
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Amaro A, Angelini G, Mirisola V, Esposito AI, Reverberi D, Matis S, Maffei M, Giaretti W, Viale M, Gangemi R et al (2016) A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity in vivo. Oncotarget 7:68803–68820 2. Avgustinova A, Iravani M, Robertson D, Fearns A, Gao Q, Klingbeil P, Hanby AM, Speirs V, Sahai E, Calvo F et al (2016) Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat Commun 7:10305 3. Bacci M, Lorito N, Smiriglia A, Morandi A (2021) Fat and furious: lipid metabolism in antitumoral therapy response and resistance. Trends Cancer 7:198–213 4. Bacci M, Lorito N, Smiriglia A, Subbiani A, Bonechi F, Comito G, Morriset L, El Botty R, Benelli M, López-Velazco JI et al (2024) Acetyl-CoA carboxylase 1 controls a lipid droplet-peroxisome axis and is a vulnerability of endocrine-resistant ER. Sci Transl Med 16:eadf9874 5. Brueffer C, Vallon-Christersson J, Grabau D, Ehinger A, Häkkinen J, Hegardt C, Malina J, Chen Y, Bendahl PO, Manjer J et al (2018) Clinical value of RNA sequencing-based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter Sweden cancerome analysis network-breast initiative. JCO Precis Oncol 2:PO.17.00135
|
|